Pfizer’s $7.3B Obesity Gamble Pays Early with MET-097i Phase 2b Success

Just one week after Pfizer announced plans to acquire Metsera for up to $7.3 billion, the obesity-focused biotech unveiled positive topline Phase 2b data for its lead candidate MET-097i, an ultra-long acting GLP-1 receptor agonist (RA) with the potential for once-monthly dosing.

Key Efficacy and Safety Results

• In the VESPER-1 trial (n=239), MET-097i achieved up to 14.1% placebo-adjusted mean weight loss at 28 weeks with weekly dosing, with some patients losing as much as 26.5% of baseline weight.
• An extension analysis at 36 weeks suggested continued weight loss without plateau, underscoring the candidate’s long-term potential.
• In the VESPER-3 interim analysis (n=268), which evaluates monthly dosing regimens, the highest titration arm showed:
  • Minimal diarrhea signal
  • Risk difference vs. placebo: +13% nausea, +11% vomiting at 12 weeks
• High study retention: VESPER-1 reported only 2.9% discontinuation, with just two participants dropping due to adverse events.

Metsera confirmed that these results enable a global Phase 3 program starting late 2025, with additional Phase 2b trials ongoing in type 2 diabetes and monthly dosing cohorts.

Strategic Implications for Pfizer

Pfizer’s acquisition of Metsera — its largest since the 2023 Seagen buyout — now appears increasingly well-timed. With danuglipron setbacks in its own pipeline, the pharma giant gains:

• Differentiated efficacy: MET-097i delivers dual-agonist-like weight loss despite being a mono-agonist, potentially matching tirzepatide at lower doses.
• Convenience advantage: Ultra-long half-life (~16 days) supports flexible weekly or monthly dosing, improving adherence compared with weekly GLP-1s like Wegovy and Zepbound.
• Pipeline expansion: Additional assets include MET-233i (ultra-long acting amylin), MET-034i (GIP agonist), an oral form (MET-097o), and a quarterly prodrug (MET-815).

Analysts suggest that even modest market share for a monthly GLP-1 RA could translate into multi-billion-dollar revenues, bolstering Pfizer’s position in the obesity and metabolic disease market.

Risks and Challenges

• Long-term tolerability and monthly dosing efficacy remain to be confirmed in ongoing Phase 2b and upcoming Phase 3 trials.
• Intense competition from Novo Nordisk and Eli Lilly, who dominate the obesity market, could constrain uptake.
• Pricing, payer coverage, and real-world adherence will be critical in determining commercial success.

Bottom Line

With robust Phase 2b efficacy and class-leading tolerability, MET-097i is emerging as one of the most promising next-generation obesity therapies. For Pfizer, the timing of the Metsera deal looks increasingly strategic, potentially securing a foothold in the evolving incretin landscape.

Reference

1. Metsera Inc. Positive Topline Phase 2a Clinical Data for MET-097i. Press release, September 29, 2025. https://investors.metsera.com/news-releases/news-release-details/metsera-reports-positive-phase-2b-results-first-and-best-class

Disclaimer: This article is for informational purposes only and does not constitute investment or medical advice.